Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00338884
Status:
COMPLETED
Last Update Posted:
2012-08-31
First Post:
2006-06-16
Brief Title:
Safety And Effectiveness Of Daily Dosing With 375 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase II Efficacy And Safety Study Of Sunitinib Malate SU011248 Administered In A Continuous Daily Regimen In Patients With Advanced First-Line Renal Cell Cancer
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase II study to allow patients with advanced kidney cancer access to sunitinib malate treatment and to find out the good and bad effects of taking 375 mg sunitinib malate in a continuous daily regimen once per day for one year
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None